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Abstract: The bioavailability of ophthalmic therapeutics is reduced because of the presence of
physiological barriers whose primary function is to hinder the entry of exogenous agents, therefore
also decreasing the bioavailability of locally administered drugs. Consequently, repeated ocular
administrations are required. Hence, the development of drug delivery systems that ensure suitable
drug concentration for prolonged times in different ocular tissues is certainly of great importance.
This objective can be partially achieved using thermosensitive drug delivery systems that, owing
to their ability of changing their state in response to temperature variations, from room to body
temperature, may increase drug bioavailability. In the case of topical instillation, in situ forming
gels increase pre-corneal drug residence time as a consequence of their enhanced adhesion to the
corneal surface. Otherwise, in the case of intraocular and periocular, i.e., subconjunctival, retrobulbar,
peribulbar administration, among others, they have the undoubted advantage of being easily injectable
and, owing to their sudden thickening at body temperature, have the ability to form an in situ drug
reservoir. As a result, the frequency of administration can be reduced, also favoring the patient’s
adhesion to therapy. In the main section of this review, we discuss some of the most common
treatment options for ocular diseases, with a special focus on posterior segment treatments, and
summarize the most recent improvement deriving from thermosensitive drug delivery strategies.
Aside from this, an additional section describes the most widespread in vitro models employed to
evaluate the functionality of novel ophthalmic drug delivery systems.
Keywords: posterior segment diseases; ocular drug delivery; hydrogels; nanocomposites; thermosensitive
systems; in vitro pharmacokinetic models
1. Introduction
One of the critical issues of topically administered ophthalmic drugs is that their efficacy is limited
by the fast drug clearance due to pre-corneal fluid drainage; consequently, frequent administrations
are required. Therefore, various drug delivery systems (DDS) have received increased attention to
enhance the efficacy of drugs on the corneal surface.
Aside from this, many limitations make it hard to deliver drugs aimed to treat eye posterior
segment diseases, such as diabetic retinopathy and age-related macular degeneration (AMD). In fact,
topical ocular medications do not reach the back of the eye; moreover, systemic administration is rarely
used because of the small volume of the eye and the presence of the blood retinal barrier (BRB) [1].
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A lot of research is currently being done to improve transscleral delivery, which might offer
the advantage of removing the need to breach the walls of the eye; many transscleral delivery
systems, also associated to iontophoresis, are therefore at different stages of development. However,
to date, the majority of treatments of the posterior segment, such as retinal and choroidal disorders,
require the intravitreal pathway. Intravitreal injection (IVI) is currently considered the most validated
option—although it is invasive and associated with serious side effects—for the delivery of large
molecules such as anti-vascular endothelial growth factors (anti-VEGF antibodies), whose use has
reached an exponential growth in recent years due to the progressive expansion of their clinical
applications [2]. Nevertheless, the periocular pathway, including the retrobulbar, peribulbar, subtenon
and subconjunctival routes, and even topical delivery, continue to be explored.
To overcome the limitations of conventional eye drops in corneal/conjunctival administration, and
of invasive injection in intraocular administrations, or of surgery-implanted cannulas in periocular
administration, in the last decades, several ophthalmic formulations, such as drug-loaded hydrogels
and contact lenses targeted to the anterior segment, or ocular implants and physical devices destined
to the back of the eye, have been proposed.
Hydrogels are three-dimensional, cross-linked networks of either synthetic or natural water-soluble
polymers with great potential in several applications, such as drug delivery, cell encapsulation and tissue
engineering [3]. Various advantages make them interesting—their aqueous environment can exert
some protection towards cells and labile drugs (such as peptides, proteins, DNA and oligonucleotides)
and they have a significant role in transporting nutrients to cells. As a result, they are attractive for
various ophthalmic applications, among which are corrective soft contact lenses [4], adhesives for
ocular wound repair [5], potential vitreous substitutes [6] and drug vehicles [7]. Regarding the latter
application, to our knowledge, most hydrogels on the market are targeted to the anterior segment
(such as Pilopine HS, Zirgan and Pilogel), due to their ability to increase viscosity and mucoadhesive
properties [8]. Conversely, just few hydrogels have been already approved by the FDA and EMA
for intraocular injectable applications; as an example, Akten (Akorn, Buffalo Grove, IIlinois), a 3.5%
lidocaine gel, was approved by the FDA for all ophthalmic procedures in October 2008, including
intraocular procedures [9,10].
Other hydrogels are currently on the market for ophthalmic application other than drug delivery
purposes—as an example, ReSure Sealant is an in situ gel approved to seal clear corneal incisions
following cataract surgery [11].
Recently, contact lenses for drug controlled delivery to the anterior chamber have been developed,
but several challenges are still arising regarding the limited drug release, the strict regulatory issues
and the high cost of clinical studies [12].
On the other hand, the crucial need to reach the eye posterior segment through less invasive
strategies other than repeated injections has boosted the development of slow-release implants that
can be placed at once at various ocular sites. Currently, intraocular implants that allow sustained
drug release in the posterior segment are at different development stages [13]. Most of these consist of
non-biodegradable polymers, such as silicone, polyvinyl alcohol and ethylene vinyl acetate, from which
long-lasting release of the entrapped drugs occurs [14]. However, they require surgical intervention
and need removal or replacement by new implants. On the contrary, biodegradable polymers such as
poly(lactic) acid and poly(lactic-co-glycolic) acid offer the advantage of releasing the drug at the same
time that the polymer degrades in the target site, avoiding the need of surgical removal [15,16].
To date, several ocular implants designed for the treatment of severe indications affecting the
posterior segment of the eye, including macular degeneration, are on the market or are undergoing
clinical trials. Among them, non-biodegradable Vitrasert, Retisert, Medidur, Iluvien and biodegradable
Posurdex, Ozurdex and Surodex must be cited [17–20]. Most of these implants are loaded with small
active compounds, such as fluocinolone acetonide, dexamethasone and ganciclovir; meanwhile no
biologics-carrying implants are available in the market, some being, however, in the pipeline [21].
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Anti-VEGF therapy, playing a central role in the pathogenesis of choroidal neovascularization, has
revolutionized the medical management of diabetic retinopathy and of AMD [22]. Currently, the most
common anti-VEGF agents are pegaptanib (Macugen), bevacizumab (Avastin) and ranibizumab
(Lucentis) [23,24], followed by other emerging macromolecular drugs already in clinical trials, among
these being Fovista (Ophthotech, Princeton, NJ, USA), a platelet-derived growth factor aptamer
currently in phase III clinical trials [25], and designed ankyrin repeat proteins [26].
The use of intravitreal administration in anti-VEGF therapy is still presenting some problems—most
drugs are rapidly cleared from the vitreous humor, inducing the need of repeated injections that
can cause side effects, such as endophthalmitis, retinal detachment, hemorrhage and poor patient
tolerance [27]; other drugs induce local toxicity when administered at their effective dose, causing
side effects and possible retinal lesions [28]. For these reasons, strategies that can deliver sufficient
drug concentrations to this anatomic region in a less invasive manner and with less frequent doses,
such as sustained-release DDS, represent an area of active interest in the ophthalmology community.
In the last decades, different technologies have been proposed to this aim, including the use of
nanomedicine [29–31]. Therapies based on nanotechnologies, such as lipid and polymeric nanocarriers,
present several advantages, allowing a precisely targeted drug delivery and controllable release of
the therapeutics [32]; moreover, the stability and half-life in the vitreous of entrapped drugs might
be enhanced, thus reducing the frequency of administration and, consequently, diminishing their
toxicity [33]. Therefore, depending on particle charge, surface properties and relative hydrophobicity,
nanoparticles (NP) can be designed to be successfully used in sustained ocular therapy [34], both
in the anterior and posterior segments [35]. Studies have shown that albumin NP can serve as a
very efficient drug delivery system for retinal diseases, such as cytomegalovirus retinitis, as they are
biodegradable, non-toxic and have non-antigenic properties [36]. Moreover, NP prepared with natural
polymers, such as chitosan, increased the intraocular penetration of loaded drugs, due to their ability
to make contact intimately with corneal and conjunctival surfaces [37]. In the past decades, several
hydrophilic polymeric particles have been proposed as ocular DDS composed of various biodegradable
polymers, such as poly(lactic acid) [38], poly(alkyl cyanoacrylate) (PACA) [39], poly(lactic-co-glycolic
acid) (PLGA) [40] and poly(ε-caprolactone) (PECL) [41]. However, one of the main barrier-hindering
clinical trials of these innovative systems is the requirement to ensure the safety of nano-microsystems
and of their biodegradation products in the eye [29,42].
Another appealing approach of drug delivery to the posterior ocular segment consists in vesicular
systems such as intravitreal-injectable liposomes (i.e., the ocular liposomal Verteporfin (Visudyne).
They provide sustained drug delivery for weeks or even months, but up until today, most of them are
only pre-clinically investigated, with few in clinical use [43].
Recently, preclinical trials have centered around the interesting formulation of nanocomposites,
consisting of nanoparticulate systems dispersed into a hydrogel matrix that provide an additional
diffusion barrier to drug release, eliminating the burst effect and extending the release profiles of the
entrapped drugs [44].
In the literature, various strategies have been proposed to deliver drugs into the eye in a more
controlled manner—in the first part of this review, special attention will be given to the thermosensitive
approach, considering the different typologies and action mechanisms. The second part deals with the
most widespread in vitro models employed to investigate the functionality of novel ophthalmic DDS.
2. Thermosensitive DDS
In recent years, significant progress has been made to control and target drug delivery by designing
“smart” systems capable of releasing a loaded drug as a response to a specific stimulus. When these
DDS are administered, drug release is activated by some local input (changes in pH level, electric and
magnetic fields, light, temperature, etc.). The stimuli responsible for activating drug release can differ
according to the nature or the type of applied energy—temperature is certainly the most exploited one
for ophthalmic application, and injectable thermoresponsive polymers have especially been proposed.
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Being characterized by the existence of a critical temperature, these systems undergo reversible
transition (due to volume collapse or phase transition to a solid or gel state) in the physiological
temperature range. Thereby, it would be possible to introduce them into the body with minimal
invasion by circumventing the need for a surgical procedure for placement of the system. Thus,
thermosensitive systems represent a very promising approach that can have practical applications in
ophthalmic research leading the advances in controlled drug delivery [28].
The following paragraphs give an overview of the most significant formulations (Table 1) able to
form an in situ drug reservoir responding to room-to-body temperature change, and of their relevant
applications in ophthalmic drug delivery, focusing upon the posterior segment.
Table 1. Types of thermosensitive drug delivery systems (DDS) for ocular administrations.
Thermosensitive DDS Mechanism
In situ hydrogels Formulation is liquid at room temperature (20–25
◦C). The contact with body
temperature (35–37 ◦C) leads to the formation of a hydrogel network
Composite systems Microparticles (MP) or nanoparticles (NP) suspended in a thermogelling matrixgenerally made of biodegradable thermosensitive polymers
Devices Polymeric materials (microneedle, punctal plug, contact lens) that, once insertedin the eye, release the loaded drug by change in temperature (from 25 to 35 ◦C)
2.1. In Situ Thermosensitive Hydrogels
In situ thermosensitive hydrogels are generally based on natural polymers, such as polysaccharides
(cellulose and chitosan) or synthetic polymers (including PEG, poly(N-isopropylacrylamide) (PNIPAM)
and Pluronic F-127) crosslinked by a variety of mechanisms [45]. Before administration they are
aqueous solutions gelling after a temperature change, owing to a temperature-induced phase transition
governed by the balance of hydrophilic and hydrophobic moieties. These systems, exhibiting low
viscosity at 23 ◦C and forming gels at 37 ◦C, have been exploited in the ophthalmic field, both for
anterior and posterior segment treatments.
One of the major drawbacks in the treatment of anterior segment diseases, commonly managed
with topical medications, is the difficulty to provide and to maintain an adequate drug concentration
in the precorneal area, as a consequence of the physiological eye removal mechanisms (lacrimation
and blinking). Thus, there is the need of an ideal dosage form able to prolong its retention time on the
eye surface.
Among the various vehicles proposed by the literature, thermo-gelling formulations are gaining
increasing interest, owing to the obvious advantages presented by shifting to the gel phase once
instilled. Several in situ gelling systems have been developed to prolong drug precorneal residence
time [46]. Sandri et al. [47] developed thermosensitive eye drops, based on chondroitin sulphate
associated with hydroxypropylmethyl cellulose, containing platelet lysate for the treatment of corneal
ulcers. Cho et al. prepared a brimonidine-loaded thermosensitive formulation of hexanoyl glycol
chitosan for glaucoma therapy that exhibited attractive bioavailability of the drug, as well as a more
prolonged period of lowered intra-ocular pressure [48]. More recently, a thermo-sensitive in situ gelling
formulation of ketoconazole based on poly(N-isopropylacrylamide)/hyaluronic acid was prepared
and tested on New Zealand white rabbits for in vivo antimicrobial studies—the increased residence
time was confirmed and a controlled drug release was obtained following topical administration in
the eye [49].
As reported above, the anatomy and safeguard barrier of the cornea compromise the rapid
absorption of drugs, thus making the topical treatment of the posterior segment quite impractical,
and making intraocular injections only just preferable that, as reported above, unfortunately can
cause heavy side effects. In situ injectable thermogelling systems have been extensively investigated
with the aim of reducing the frequency of intraocular injection acting as sustained drug release
depot [50,51]. Various polymers are capable of forming thermosensitive injectable hydrogels with a
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transition temperature of ∼32 ◦C. PNIPAM and its copolymers are among the most intensively
investigated for ophthalmic application, primarily for their biocompatibility [52,53]. Derwent
and colleagues employed PNIPAM cross-linked with poly(ethylene glycol) diacrylate (PEG-DA)
to successfully encapsulate proteins, including bovine serum albumin (BSA), immunoglobulin G
(IgG) and, finally, bevacizumab and ranibizumab. These kinds of hydrogels exhibited fast and
reversible phase changes with alteration in temperature, and their release profiles resulted as a
function of the cross-link density [54,55]. In other research studies, copolymers based on acrylic
acid N-hydroxysuccinimide (NAS), N-isopropylacrylamide (NIPAM) and increasing concentrations
of acryloyloxy dimethyl-γ-butyrolactone (DBA) and acrylic acid (AA) were synthesized with the
aim to obtain thermoresponsive, resorbable copolymers suitable to deliver drugs and/or cells to the
posterior segment of the eye in a minimally invasive manner [56,57]. Copolymers of NIPAM and
NAS were also conjugated with cell adhesive peptides and amine-functionalized hyaluronic acid.
These novel copolymers were designed by Mazumder et al. [58] to provide non-invasive delivery of
therapeutic cells into the hard-to-access sub-retinal space for the treatment of retinal diseases. More
recently, bevacizumab was delivered in a biodegradable, thermoresponsive hydrogel, poly(ethylene
glycol)-poly-(serinol hexamethylene) ESHU, that, according to in vitro/in vivo experiments, resulted
well-tolerated and capable of sustaining bevacizumab release [59,60].
PEG-PLA-based hydrogels have also been considered, and many attempts have been taken to find
those with a critical gelation temperature (LCGT) resembling body temperature [61]. PLGA-PEG-PLGA
copolymer was found to be an efficacious thermosensitive in situ gel-forming material for ophthalmic
drug delivery [62]. In vivo pharmacokinetic studies showed that, through an intravitreal injection of
PLGA-PEG-PLGA hydrogel in adult male Sprague Dawley rats, the overtime release of bevacizumab
in the vitreous humor and retina was greatly extended [63]. The same (PLGA–PEG-PLGA) triblock
copolymer was used as an injectable biocompatible matrix for the intravitreal release of hydrophobic
glucocorticoid dexamethasone (DEX). It was possible to conveniently modulate its in vitro release
rate from the thermogel by varying the mixing ratio of the two copolymers [64]. Interestingly, Patel
and colleagues successfully synthesized an injectable in situ hydrogel composed of biodegradable
pentablock copolymers, such as PEG, PCL and PLA for controlled ocular protein delivery. Compared
to triblock copolymers, pentablock copolymers exhibit significantly reduced crystallinity and higher
biocompatibility [65].
The poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) triblock
copolymers, known as Pluronics (BASF) or Poloxamers (ICI), have been widely used as non-ionic
surfactants, solubilizers and DDS. Because of the lower critical gelation concentration and the lowest
toxicity in the commercially available Pluronics series, Pluronic F127 (Poloxamer 407) has been studied
most extensively as a DDS. Nonetheless, Pluronic hydrogels have several drawbacks, such as poor
gel durability, weak mechanical strength and rapid drug release. To overcome such disadvantages,
Pluronic-based grafted polymers have been proposed as an injectable and sustained delivery system
of human growth hormone [66]. Among these, an amine-terminated Pluronic F127 was grafted
with hyaluronic acid (HA). The obtained Pluronic-HA hydrogel showed a lower critical gelation
concentration and dissolution rate, with a consequently slow drug release rate [67]. Bhoyar and
colleagues evaluated different gelling solutions made with Poloxamers in combination with several
polymers (HPMC, Chitosan, PVP, PVA) for the sustained intravitreal release of ciprofloxacin. Increase
in Poloxamer concentration within the range of 18–24% w/w showed a decrease in phase transition
temperature. The addition of HPMC decreased the percentage of drug released. PVP with Poloxamer
failed in optimization, while PVA did not show to have any effect on phase transition but increased
drug release efficiency [68].
Because of its non-toxicity, biodegradability, biocompatibility, stability and bioadhesive properties,
chitosan and related derivatives have been explored as a thermosensitive hydrogel system for biomedical
applications in injectable products, whose technological and biological requirements are quite similar to
those of ophthalmic formulations [51]. Chitosan is often included in ophthalmic formulations because
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of its biocompatibility and biodegradability, permeation enhancing and corneal wound healing effects,
antimicrobial and antifungal actions and strong mucoadhesive nature. Associating chitosan with
stimuli-responsive polymers increases the mechanical strength of the formulation, resulting in better
compliance and an increased therapeutic effect [69].
Chung and colleagues [70] proposed either Pluronic-chitosan or PNIPAM-chitosan [71] copolymers
as matrices of injectable and thermoreversible hydrogels. A thermosensitive hydrogel system based on
chitosan and PVA was also reported [72] and recently, a new chitosan-dibasic orthophosphate hydrogel
with thermoreversible gelation was developed by Ta and colleagues [73].
Finally, Hu and colleagues [74] recently proposed a novel hydrogel composed of thermoresponsive
block copolymers of methoxy-PEG-PLGA cross-linked with 2,2-bis (2-oxazoline), which had a sol-gel
behavior phase transition. Sustained release of bevacizumab was obtained in vitro up to 30 months
without burst effect, and after 1 month of intravitreal injection it had no cytotoxicity in vivo on retina
cells. Therefore, also thanks to its intraocular characteristics of biodegradability and bioactivity,
it appeared to be a promising intravitreal injection carrier for bevacizumab delivery.
2.2. Thermosensitive Composites
NP and microparticles (MP) are colloidal systems that, in addition to the advantages similar to
those of liposomes, provide flexibility in routes of administration, are tunable in size and have a surface
whose functionality can be made responsive to external stimuli [75,76]. MP or NP suspended in a gel
matrix (composite systems), generally made of biodegradable polymers, are emerging as a versatile
platform in ocular drug delivery applications and may provide reduced side effects, lowering the
frequency of intraocular injections [77–79].
Tan and colleagues [80] recently developed an interesting thermosensitive in situ gelling
formulation, consisting of nanostructured lipid carriers (NLC) incorporated in a hydrogel
of hydroxypropyltrimethyl ammonium chloride chitosan and β-glycerophosphate, to form a
NLC-loaded hydrogel carrier for ocular sustained release. In in vitro release studies, the resulting
dexamethasone-loaded formulation showed a sustained drug release, as 88.65% of the total drug
was released from the nanocomposite within 3 days, while almost the same amount was released
from simple NLC in 48 h. Therefore, dexamethasone-based NLC gel seemed to be a promising drug
delivery system.
Fedorchak et al. [81] developed and tested a combined thermoresponsive hydrogel/microsphere eye
drop that was administered like a traditional eye drop, but was able to form a pliable, non-degradable
depot after exposure to body temperature in the conjunctival cul de sac. Fabiano and co-workers [82]
developed a nanocomposite system composed of 5-fluorouracil (5-FU)-loaded NP dispersed in
thermosensitive hydrogel made of chitosan and its quaternary ammonium conjugates.
These formulations and that not containing NP were instilled in rabbits, and the 5-FU transcorneal
penetration was measured by analyzing the aqueous humor. Both systems increased the area under
the curve 3.5 times compared with the phosphate buffer 5-FU solution, chosen as reference. The results
underlined the ability of hydrogels to control drug release to a zero order and that of NP to be
internalized by cornea cells. Therefore, this nanocomposite formulation can be assessed as an
interesting ophthalmic sustained-release DDS. Ammar and colleagues [83] observed the improvement
of ocular bioavailability, onset and duration of action of dorzolamide hydrochloride when formulated
in an in situ gel nanoemulsion-based delivery system for precorneal application. Poloxamer 407, with
its thermoreversible gelation and surface active properties, was utilized to formulate this gel-forming
system, and an improvement of ocular drug bioavailability was demonstrated.
While the thermoresponsive composites described above were designed for precorneal treatments,
a number of formulations based on MP or NP incorporated into thermosensitive gels are described in
the literature as useful injectable systems for cell and therapeutics intraocular delivery (Figure 1).
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Figure 1. Possible scheme of preparation and intravitreal injection of a thermosensitive nanocomposite
system: (a) Drug loaded NP are suspended in a polymeric solution at 25 ◦C. (b) Polymeric
solution-suspended NP form a fluid injectable nanocomposite system at 25 ◦C. (c) The fluid
nanocomposite system is injected in the vitreous at 25 ◦C; the temperature-induced phase transition
occurs at 35 ◦C, resulting in in situ gel formation and sustained drug release.
Gao et al. [84] designed and developed a drug-delivery system containing a combination of
poly(d,l-lactide-co-glycolide) (PLGA) MP and alginate hydrogel for the sustained release of retinoids
to be used in the treatment of retinal blinding diseases. Increased electroretinogram responses were
observed after subcutaneous injection of the resulting system in mice, offering a potential alternative to
maintain and even to restore vision in humans with certain forms of hereditary blindness.
Hirani and colleagues [85] developed a DDS composed of triamcinolone acetonide-encapsulated
PEGylated PLGA NP incorporated into PLGA-PEG-PLGA thermoreversible gel: it resulted in
non-cytotoxicity to adult retinal pigment epithelial cell line-19 (ARPE-19) cells and was effective
in reducing in vitro VEGF expression when compared to pure triamcinolone.
In another study [86], poly(lactic-co-glycolic acid) (PLGA) microspheres obtained by a
modified solvent evaporation from the double-emulsion technique were suspended in an injectable
poly(N-isopropylacrylamide)-based thermo-responsive hydrogel. The developed microsphere-hydrogel
DDS resulted in an advantageous ocular DDS for anti-VEGF agents (ranibizumab or aflibercept) with the
potential of releasing both the bioactive molecules for 196 days.
Biodegradable doxorubicin (DOX)-loaded poly(d,l-lactide-co-glycolide)-poly(ethylene
glycol)-folate (PLGA-PEG-FOL) micelles (DOXM) were prepared and suspended in PLGA-PEG-PLGA
thermosensitive gel. DOXM exhibited higher cellular uptake than pure DOX in overexpressing folate
receptor Y-79 cells, proving their ability to act as a promising targeted delivery system for anticancer
agents to retinoblastoma cells following intravitreal administration [87].
Famili et al. [88] developed drug-loaded polymeric micelles dispersed in a thermosensitive gel as an
injectable ocular delivery system for triamcinolone acetonide (TA), a very poorly soluble corticosteroid.
As a matrix gel they used poly(urethaneurea) backbone, partially grafted with the temperature-sensitive
poly(N-isopropylacrylamide) (PNIPAAm), whilst micelles were composed of tri-block copolymer,
including a high molecular weight polyurethane capped by poly-ethyleneglycol (PEG). To obtain
TA-loaded micelles, two methods were employed: a traditional emulsification-sonication procedure
and an extrusion method. In vitro tests proved that the combined system significantly improved
TA kinetics, sustaining the release for approximately one year. Clinically, this system represents a
significant improvement over the current intravitreal injections of corticosteroid suspensions because
of its biocompatibility, degradability, long-term TA release profile and ease of administration—indeed,
it can be injected through down to 32-gauge needles, well tolerated by patients.
More recently, Agrahari et al. designed composite nanosystems based on biodegradable
pentablock copolymers, such as polylactic acid, polyglycolic acid, polycaprolactone and PEG to
obtain sustained-release formulations suitable to deliver macromolecules to the posterior eye. In a
previous study, pentablock copolymers (PB-1 and PB-2) were successfully synthesized by ring-opening
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bulk copolymerization of ε-caprolactone; then, IgG-Fab was encapsulated into NP of the pentablock
copolymer (PB-1 NPs) using the water-in oil-in water double emulsion solvent evaporation method.
Finally, IgG-Fab-loaded PB-1 NP were suspended in the thermosensitive PB-2 gelling copolymer.
The resulting composite nanoformulation exhibited a sustained delivery, a negligible burst release and
a near zero-order release for 80 days in vitro. To assess cell viability and biocompatibility, the same
formulation was tested on ocular cell lines and they resulted in being safe for clinical applications [78].
In a second research work, the same authors used different molecular weight polymers (PEG, polylactic
acid and polycaprolactone) to prepare NP that were then dispersed in a thermosensitive gel obtained
by sequential ring opening bulk polymerization. To evaluate the effect of molecular weights on release
profiles, they used three macromolecules (lysozime ~14.5 kDa, IgG-Fab ~50 kDa and IgG ~150 kDa).
Results showed a minimal burst release and a sustained drug release from the composite nanosystem;
the safety of pentablock copolymers were assessed by in vitro biocompatibility studies, showing the
possibility to use these innovative composite nanosystems to deliver macromolecules to the eye for a
prolonged time [89].
A summary of all these recently proposed thermosensitive nanocomposites is reported in Table 2,
together with the thermosensitive in situ forming hydrogels described above.
2.3. Thermosensitive Devices
In addition to thermosensitive formulations, the literature reports the development of microneedles
as alternative DDS to topical, systemic or intraocular administration for the treatment of posterior
segment diseases. Jiang et al. [90] demonstrated that the insertion of coated microneedles via
intrascleral and intracorneal routes could be a useful ocular DDS. An interesting method that combines
microneedle technology with the advantages of thermosensitive in situ gelling is described by Thakur
and co-workers [91]—they tested a minimally invasive hollow microneedle ex vivo on whole rabbit
eyeballs to release in situ self-assembling thermoresponsive poloxamer-based implants into the scleral
tissue, which were able to give a sustained drug delivery. The release of fluorescein sodium from these
intrasclerally-injected implants was studied, and the implant localization and scleral pore-closure were
examined by optical coherence tomography. Sustained release of the model molecule was obtained,
varying with the needle heights and the region of intrascleral injection.
Tunc et al. [92] used Parylene C (poly(monochloro-p-xylylene)) and poly(dimethyl siloxane)
(PDMS) coated with PNIPAM as implant materials by following pars plana vitrectomy. Three
implants of PNIPAM-coated parylene and three of PDMS were inserted over the retina in six rabbits.
In vivo results evidenced that PNIPAM-coated implants are able to adhere to the retina without
significant ocular toxicity in the short term and can prevent retinal detachment. Thermosensitive
hydrophobic acrylic materials such as SmartPLUG, composed of biocompatible and thermosensitive
poly(stearylmethacrilate) with methylmethacrylate, have been in use since 2002. These polymers are
combined to form materials with glass transition temperature (Tg) or melting temperature (Tm) below
human body temperature (37 ◦C). After administration into the eye, they expand with the subsequent
fixation to the patient’s punctum or canaliculum. Recently, punctal plugs (PPs), originally introduced
as lacrimal occlusive devices for the management of dry eye disease, have been proposed for ocular
DDS [93]. These systems, loaded with poor ocular bioavailability drugs, can be useful to obtain a
desired release rate with a significant increase in bioavailability [94]. Moxifloxacin (MOX)-loaded
PPs [95] were developed (Ocular Therapeutix, Bedford, MA, USA) to extend the drug release in the
bacterial treatment of conjunctivitis.
Hyun Jung Jung and Anuj Chauhan [96] designed temperature-sensitive contact lenses to induce
ophthalmic drug delivery. In particular, they prepared timolol-loaded NP and dispersed them in
polymer gels. The particle-loaded p-HEMA gels were synthesized by free radical polymerization of
the HEMA monomer mixed with the timolol-loaded NP. In vitro release experiments evidenced that
NP loaded gels can be used as contact lenses that are able to release the drug upon insertion in the eye.
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Table 2. A summary of the thermosensitive systems (hydrogels and composites) developed for ocular drug delivery.
Drug Delivery
Systems (DDS) Material/Aim Molecule Delivered Observation References
In situ hydrogel Poly(N-isopropylacrylamide) (PNIPAM) crosslinked with poly(ethylene glycol)diacrylate (PEG-DA) as an intravitreal injectable vehicle.
Proteins, Ig,
Bevacizumab,
Ranibizumab
Release profiles function of the cross-link density. Release sustained for
approximately 3 weeks. [54]
In situ hydrogel
Copolymers of N-isopropylacrylamide (NIPAM), acrylic acid
N-hydroxysuccinimide (NAS) and varying concentrations of acryloyloxy
dimethyl-c-butyrolactone (DBA) and acrylic acid (AA) for intravitreal injections.
Dexamethasone Slow-degrading copolymers (over 130 days of incubation in PBS),injectable from a 30-gauge needle, offering slow drug release. [56,57]
In situ hydrogel
Copolymers of NIPAM and acrylic acid N-hydroxysuccinimide (NAS)
conjugated with amine-functionalized hyaluronic acid (HA) as a biomaterial
scaffolds for bolus injection into the sub-retinal space.
Cells Temperature-induced scaffold formation for transplanted cells entrapment;optimal compatibility with retinal pigment epithelial. [58]
In situ hydrogel PEG-poly-serinol hexamethylene (ESHU) as an intraocular drug-delivery vehiclefor age-related macular degeneration (AMD). Bevacizumab
The release of bevacizumab was sustained up to 17 weeks and its
concentration was maintained averaging 4.7 times higher than that in eyes
receiving bevacizumab bolus injections. Biodegradable.
[59,60]
In situ hydrogel Poly(lactic-co-glycolic acid) (PLGA)-PEG-PLGA triblock as an intravitrealinjectable hydrogel for sustained drug release. Bevacizumab
Hydrogel immediately formed after intravitreal injection; in vitro
sustained drug release over a period of up to 14 days. [63]
In situ hydrogel PLGA-PEG-PLGA triblock as an intravitreal injectable hydrogel for sustaineddrug release. Dexamethasone
Drug ocular retention time was prolonged from several hours to more than
1 week after a single intravitreal injection; excellent biocompatibility. [64]
In situ hydrogel PLA-PCL-PEG pentablock-based injectable hydrogel for the treatment ofposterior segment neovascular diseases. IgG
Significantly longer sustained release of IgG was provided by pentablock
(more than 20 days) respect to triblock copolymers. [65]
In situ hydrogel Poloxamer 407 in combination with other polymers to form a topical in situ gel. Ciprofloxacin Improved antimicrobial effect in vitro compared to the market eye drops.Eight hour sustained release of ciprofloxacin. [68]
In situ hydrogel mPEG-PLGA cross-linked with 2,2-bis (2-oxazoline) aqueous solution as anintravitreal injection carrier. Bevacizumab
Thermoresponsive, controlled drug release. Intraocular biocompatibility
biodegradability and bioactivity of loaded drug. [74]
Nanocarriers inin
situ gel
Nanostructured lipid carriers (NLC) in thermoreversible HACC/GP gel for
topical ocular delivery. Dexamethasone Precorneal sustained release of drug from NLC-HACC/GP gel in vitro. [80]
In situ gelled
nanoemulsion Poloxamer 407 and Poloxamer 188 in nanoemulsion for topical ocular delivery.
Dorzolamide
hydrochloride Increased precorneal residence time and bioavailability. [83]
NP in hydrogel PEG-PLGA NP in PLGA–PEG–PLGA thermoreversible intraocular injectable gel. Triamcinoloneacetonide
Non-toxic and able to reduce vascular endothelial growth factor (VEGF)
levels in ARPE-19 cells; sustained release of the drug over 10 days. [85]
NP in hydrogel PCL-PLA-PEG-PLA-PCL-based NP in thermosensitivemPEG-PCL-PLA-PCL-PEGm intraocular injectable gel. IgG-Fab
Minimal burst release with near zero-order release profile from the
composite nanoformulation up to 80 days. In vitro cell viability and
biocompatibility.
[78]
Micelles in
hydrogel
PLGA-MP in poly(N-isopropylacrylamide) as an injectable MP-hydrogel drug
delivery system.
Ranibizumab and
Aflibercept Controlled and extended intraocular release for approximately 200 days. [86]
Micelles in
hydrogel
Poly(d,l-lactide-co-glycolide)-poly(ethylene glycol)-folate (PLGA-PEG-FOL)
micelles in PLGA-PEG-PLGA thermoreversible gel for intravitreal
administration.
Doxorubicin Sustained drug release for 2 weeks; increased drug uptake in Y-79 cellsoverexpressing folate receptors. [87]
Micelles in
hydrogel PEG-PHS-PEG micelles in PNIPAM-PSHU backbone as an injectable ocular DDS.
Triamcinolone
acetonide Sustained long-term drug release and reduced burst release. [88]
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3. In Vitro and In Silico Models to Test Intraocular DDS
Currently there is a lack of convenient platforms for the treatment of posterior eye diseases,
as several aspects of ocular drug delivery, such as distribution, clearance and overcoming barriers
by drugs, are not completely understood. Meanwhile, corneal and conjunctival epithelia play an
important role for topically administered ophthalmic drugs in the development of alternative therapy
for the back of the eye. It is important to know the crucial role of the retina, the thin light-sensitive
membrane that lines the inner surface of the eye and that, together with the retinal pigment epithelium
(RPE), constitutes the blood retinal barrier (BRB) [97]. Intravitreally administered drugs distribute in
the vitreous and to the surrounding ocular tissues. Their elimination from the vitreous cavity occurs
via blood-ocular barriers and aqueous humor outflow.
In parallel, the knowledge of pharmacokinetic (PK) profiles of intraocular administered drugs
is essential to determine the minimum dosing frequency to achieve the maximum therapeutic
concentration. Several researchers analyzed the PK parameters of intravitreal-injected drugs in rabbit
eyes with the employment of animal tests [98]. Overall, traditional PK studies of eye dissection yielded
important information about the mechanisms, even if these approaches are affected by some limitations.
The employment of magnetic resonance imaging (MRI) was useful in assessing drug penetration
through ocular barriers, the location of ocular and periocular depots, the release kinetics from ocular
implants and the clearance process kinetics [99].
Moreover, the use of in vivo models makes the results difficult to evaluate, to compare and to
correlate, especially whenever eye dissection is required [100]. The challenge is to design alternative
experimentally controlled models that give more reproducible data, reducing animal use, and with
consequent cost reductions and ethical advantages.
The current trend is to develop in vitro models able to evaluate PK parameters of drugs considering
their physico-chemical properties and by mimicking anatomical and physiological factors. Such models
are being increasingly employed in the preclinical stage during drug discovery and development; they
can also be used to establish in vitro–in vivo correlations and in quality control procedures. A typical
approach is to combine in vitro data with in silico results to build a model whose performance has to
be tested in animal experiments [101].
As an example, the USP4 dissolution apparatus has often been used to test the dissolution of
poorly soluble drugs and sustained-release tablets [102,103]; meanwhile, in vitro methods based on
freshly explanted animal corneas/eye bulbs mounted on diffusion cells are generally employed to
evaluate transcorneal and transcleral drug permeation [104–106]. Even though these model systems
are very useful for initial screening, they have limitations in that they consider neither the human
eye compartmentalization nor the mass transfer process induced in the vitreous humor by the outer
aqueous flow. From this perspective, Liu and Wang developed an ex vivo method, which allows for
the evaluating the precorneal residence time of ophthalmic formulations. This method consisted in
a freshly excised rat cornea placed on a chamber perfused with normal saline solution through two
precision pumps controlling the in/out flow rates [107].
To simulate the physiological condition, in addition to the perfusion, an efficient model might
also mimic the vitreous motion induced by saccadic eye movements. In a recent work, Repetto and
colleagues [108] presented a model consisting in a spherical chamber able to rotate at a scheduled
time. Based on this apparatus, Bonfiglio et al. [109] developed a magnified scale model of the vitreous
chamber suitably modified to evaluate the aspects of drug distribution in the vitreous.
A test method simulating the in vivo situation, called the Vitreous Model, was developed by Loch
and colleagues to observe the release behavior of ophthalmic dosage forms, such as intravitreal injections
or implants, and the consequential drug distribution in the vitreous body [110]. The same group
developed a multi-layer diffusion cell with the purpose of simulating some of the critical parameters
that influence drug release and distribution from dosage forms injected in the subconjunctival or
intrascleral region [111].
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Greater insight is provided by the work of Awwad et al. [112]—these authors proposed an in vitro
eye model adapted to human size, consisting in two compartments assembled in such a way as to
reproduce the aqueous flow and the mass transfer through the anterior route. This model, named
PK-Eye, was employed to assess the PK parameters (clearance, residence time, release profiles, etc.)
of therapeutic proteins, such as ranibizumab, bevacizumab and triamcinolone acetonide suspension,
and resulted in a promising preclinical tool to study novel long-lasting therapeutics targeted to the
posterior segment.
Recently, this model has been refined by our research group [113], which designed and developed
a three-compartment ocular flow cell. Similarly to the PK-Eye model cited above, this new model
can be filled with simulated vitreous (agar and hyaluronic acid-based); in addition, it contains a
semipermeable disk between the central and the posterior section that can act as a support for retinal
cells (Figure 2).
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Figure 2. Ocular three-compartments flow cell developed in our laboratory with the semipermeable
disk support for retinal cells (red circled).
In the literature, several papers report the transport behavior of intravitreally administered small
and large molecules; results are often obtained by in vivo and ex vivo experiments performed for a few
hours. In the case of intravitreally injected protein formulations, it is helpful to follow the stability as a
function of time. Accordingly, Patel and colleagues [114], to predict the stability of three intravitreal
monoclonal antibodies, developed ex vivo static, semi-dynamic and dynamic models called ExVit.
With the ExVit static model, it was observed that a significant precipitation and aggregation
of proteins, probably due to pH level change, occurred in the vitreous humor (VH) after isolation.
The semi-dynamic model consisting in two compartments, the VH- and buffer-compartment, effectively
stabilized the pH level and facilitated the migration of degradation products. However, the
semi-dynamic model did not completely overcome the limitations related to evaluation of long-term
protein stability. Therefore, the same researchers designed a dynamic model comprising three
diffusion controlling barriers (two membranes and a gel-matrix) to modulate the diffusion rate of
macromolecules. More recently, the same group proposed an ex vivo intravitreal horizontal stability
model employed to assess the long-term stability of a bi-specific monoclonal antibody (mAb) named
ExVit-HS. It consisted of a two-compartment dynamic model (VH- and buffer-compartment) separated
by a diffusion controlling membrane (MWCO of 50 kDa) [115]. The vitreous-compartment was filled
with VH isolated from porcine eyes with an incision placed near the conjunctiva. The results suggested
that the ExVit-HS model can be considered a valuable tool for evaluating long term stability of protein
drugs and of other therapeutic molecules that are intravitreally injected.
As previously reported, the fate of the drugs following systemic injection or IVI is influenced by
the presence of BRB and RPE permeability. However, the information about this topic is currently
controversial. Leena Pitkänen et al. [116] provided permeability values of RPE-choroid as a function
of molecule size and lipophilicity. They employed an in vitro diffusion apparatus consisting of a
vertical diffusion chamber in which a bovine RPE-choroid was blocked. The permeation data were
determined both inward (choroid-to-retina) and outward (retina-to-choroid). Previously, Steuer and
colleagues [117] developed a protocol to isolate the porcine BRB in a rapid and gentle way and explain
how to immobilize the intact tissue in a two-chamber polycarbonate device. This RPE model showed a
large permeability dynamic range, proving to be a valuable tool for research of BRB drug penetration.
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Over recent years, some cell culture models mimicking ocular barriers have been proposed and
are considered as a useful alternative to in vivo toxicity tests to investigate pathological conditions and
the toxicological screening of compounds [118]. However, these models are affected by several intrinsic
restrictions, mainly because they are formed by cell monolayers grown on a two-dimensional (2D)
culture scaffold, which does not take into account the behavior of cells in the three-dimensional (3D)
curved native ocular tissue. Therefore, ophthalmic research is strongly interested in developing
3D ocular in vitro models for toxicity testing, safety screening and evaluating long-term drug
effects [119,120]. 3D models are more suitable to create a cell-based platform whose responses
will be as representative as those obtained in in vivo conditions.
Recently, Postnikoff et al. [121], in the attempt to reproduce the curved cell growth conditions,
cultured human papillomavirus-immortalized cells on a curved Millicell-HA membrane. They obtained
a stratified, curved epithelial model and employed it to study the biocompatibility of benzalkonium
chloride, a preservative widely employed in commercial eye drops. The results underlined the
suitability of this model for biocompatibility experiments.
Nowadays, most of the in vitro ocular models described in this review and summarized in Table 3
are in the pipeline and need further investigation.
Table 3. In vitro ocular pharmacokinetic models.
Model Molecules Delivered Outcomes References
Dissolution apparatus (USP4) with a 1.5
mL/min flow (8–19 mL chamber)
Model drugs loaded in
ocular implant
Adequate sensitivity; correlation
with in vivo conditions [102]
Spherical cavity, magnified with respect
to the real geometry, carved within a
Perspex cylinder and able to rotate
Blank glycerol solution
First attempt to measure the flow
field induced by saccadic eye
movements on a model of the
vitreous chamber
[108]
Plexiglas cylinder with an internal
spherical cavity, magnified with respect
to the real geometry, able to rotate
Model drug particles
Three-dimensional (3D)
understanding of the
saccade-induced steady component
of the vitreous flow
[109]
Spherical glass corpus filled with a
polyacrylamide gel placed on an altered
orbital shaker
Fluorescein sodium
solution
Good accordance of the results with
the porcine vitreous humor [110]
Multi-layer diffusion cell composed of
three layers placed on top of each other,
perfused with buffer using a
multi-channel pump
Fluorescein sodium
solution
Opportunity to simulate the
choroidal and conjunctival blood
flow in a simplified setup
[111]
Two-compartment in vitro eye flow
model (pharmacokinetic (PK)-Eye)
Dye (Coomassie Brilliant
Blue)
To mime the intraocular aqueous
outflow for vitreous clearance times
estimation for proteins and poorly
soluble drugs (injectable
suspensions or implants)
[112]
Ex-vivo intravitreal horizontal stability
model (ExVit-HS)
Bi-specific monoclonal
antibody (mAb)
Valuable tool to evaluate protein
and other drugs stability after IVT
injection
[115]
Isolated bovine retinal pigment
epithelium (RPE)-choroid sealed in a
vertical diffusion chamber
FITC-dextran
Useful for pharmacokinetic
simulation, particulalrly to evaluate
the the retinal entry of drugs after
transscleral and systemic delivery
[116]
Reconstructed corneal epithelium in the
shape of the regular human cornea Benzalkonium chloride
Suitable for biocompatibility
experiments [121]
Computational modeling can also provide information about drug distribution within the
vitreous of animals and humans after injection or release by implants [122–124]. However, these
mathematical models are limited, as they neither consider nor discuss the stability and interactions of
proteins/excipients with the vitreous humor components.
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Aapo Tervonen et al. [125] developed a computational model of the physical barrier function of
the outer BRB, reflecting the corneal model of Edward and Prausnitz [126] and aiming to relate the
properties of the molecule, such as the lipophilicity and radius, to the permeability of the material
and to the tissue diffusion pathways. They also introduced a tight junction model structure for the
epithelial model.
4. Conclusions
Pharmacologists and drug delivery scientists consider ocular drug delivery as a major challenge,
owing to the particular anatomy and physiology of the eye and to the presence of various static and
dynamic barriers. Topical drug delivery is used generally to treat anterior segment disease, as most of
the instilled drop is unable to reach the posterior segment of the eye, meanwhile intraocular injections,
mainly IVIs, are considered a gold standard for the treatment of posterior segment diseases. Aside
from this, several studies have reported the efficacy of periocular and intravitreal injections, as well as
those of intravitreal implants; however, high administration costs hinder their effective application.
A number of potential serious risks are also involved, such as retinal detachment, increased intraocular
pressure endophthalmitis and cataractogenesis.
Recently, a variety of intraocular controlled-release DDS has been developed with the aim to
deliver drugs at a stable concentration over an extended period in patients with conditions affecting the
posterior segment, including uveitis, macular edema and AMD. The understanding of such drugs’ PK
and the comprehension of the physiological barriers of ocular tissues is essential to the establishment
of a valid strategy to reduce side effects of intraocular injections.
The main content of this review was the analysis of the literature, with a special focus on the
recently developed thermosensitive systems (hydrogels, composites and devices) proposed as strategies
to increase the level of safety and efficacy and to reduce the side effects of ophthalmic treatments.
This review also summarized preclinical in vitro models employed to evaluate the performance of
innovative intraocular DDS.
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